Date: 04/02/2019 HERCULES, Calif.–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the appointment of Ilan Daskal as Executive Vice President and Chief Financial Officer, effective April 6, 2019. Mr. Daskal comes to Bio-Rad from Lumileds, where he served as Chief Financial Officer. He... Read more
Date: 02/14/2019 HERCULES, Calif.–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug... Read more
Date: 01/03/2019 HERCULES, Calif.–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Christine A. Tsingos has informed the company of her intention to retire as Executive Vice President and Chief Financial Officer effective April 30, 2019. Ms. Tsingos will remain in her current... Read more
Date: 12/03/2018 HERCULES, Calif.–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced expanded global access of the company’s quality controls across multiple Abbott clinical diagnostics platforms that now includes the Abbott Alinity ci-series instruments. “We are pleased to fulfill this need and offer customers... Read more
Date: 11/14/2018 HERCULES, Calif.–A Federal District Court jury yesterday found that 10X Genomics willfully infringed three United States patents owned by the University of Chicago and exclusively licensed to Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products (NYSE: BIO and BIOb). In awarding Bio-Rad $23.9 million in damages, the... Read more
Date: 11/13/2018 HERCULES, Calif.–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that the company has been awarded a contract for iQ-Check real-time PCR pathogen detection test kits and the iQ-Check Prep Automation System from the United States Department of Agriculture’s Food Safety and... Read more
Date: 10/29/2018 HERCULES, Calif.–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the IH-Reader 24, a semi-automated blood typing instrument designed for medium- to small-volume laboratories. A combination centrifuge and... Read more
HERCULES, Calif. — January 22, 2018 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the IH-Incubator L and IH-Centrifuge L instruments to be used with the full range of Bio-Rad’s IH-System... Read more